What Shandong Luoxin Pharmaceutical Group does

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. is a vertically integrated Chinese pharmaceutical conglomerate headquartered in Linyi, Shandong Province, with three manufacturing bases across Shandong, Shanghai, and Chengdu, and nearly 6,000 employees. The company is publicly listed on the Shenzhen Stock Exchange (Stock Code: 002793.SZ) following a 2019 A-share relisting, having previously listed on the Hong Kong H-share market in 2005. Its core competencies span active pharmaceutical ingredient (API) manufacturing across 10+ therapeutic categories (anti-infectives, cephalosporins, quinolones, oncology, respiratory, digestive, nervous system, endocrine, cardiovascular, and anti-inflammatory), finished dosage form production (tablets, capsules, freeze-dried powder injections, sprays, aerosols, prefilled syringes), and innovative drug development. The company holds 309 drug production licenses, 48 national new drug certificates, and 200 Chinese invention patents, with flagship product Tegoprazan (Taixinzan®) being China's first P-CAB (potassium-competitive acid blocker) drug approved for three indications (H. pylori eradication, reflux esophagitis, duodenal ulcer), all included in the National Reimbursement Drug List by 2024.

The business operates across four revenue streams: (1) bulk API sales with international DMF registrations across India, Japan, Korea, Vietnam, and Egypt; (2) finished dosage form marketing of over 300 products across 48 national new drugs; (3) licensed product commercialization from international partners (JW Holdings, Marinomed Biotech AG, HK inno.N Corporation, Aurobindo Pharma) involving upfront payments, milestone payments, and tiered royalties; and (4) integrated healthcare services. GTM motion is predominantly sales-led through a nationwide direct provincial sales network with dedicated business divisions, complemented by international business departments covering the Americas, Southeast Asia, CIS, Africa, and Asia Pacific. The customer base is hospitals, healthcare providers, and pharmaceutical manufacturers across multiple therapeutic areas, with no disclosed customer concentration risk to a single buyer.

Revenue figures are not publicly disclosed. The company has been consistently ranked among the top 100 Chinese pharmaceutical enterprises since 2006 (No. 28 in 2015-2016), recognized as National High-Tech Enterprise, National Technological Innovation Model Enterprise, and won the Second Prize of National Scientific and Technological Progress Award in 2017. Manufacturing scale supports annual capacity of 1 billion powder injections, 500 million freeze-dried powder injections, 7 billion tablets, and 2 billion capsules. The company maintains international GMP certifications (ISO 9001, ISO 14001, J-GMP, Korean GMP) and operates joint ventures and licensing arrangements that collectively signal a hybrid legacy generic manufacturer model transitioning toward innovative drug commercialization.

Name

Shandong Luoxin Pharmaceutical Group

Legal name

山东罗欣药业集团股份有限公司 (Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.)

Website

https://luoxin.cn

Company type

Public

Founded year

1988

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Shandong Luoxin Pharmaceutical Group is a vertically integrated Chinese pharmaceutical company (Shenzhen Stock Exchange: 002793.SZ) that develops, manufactures, and commercializes APIs and finished dosage forms across 10+ therapeutic categories, serving hospitals, healthcare providers, and pharmaceutical manufacturers domestically and internationally, with its flagship P-CAB drug Tegoprazan being China's first triple-indication approval.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG), Small-Molecule Generics (Branded/Unbranded) (HLAIABAA), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• Generic pharmaceuticals
• Active pharmaceutical ingredients
• Finished dosage forms
• Drug manufacturing
• Pharmaceutical licensing

Headquarters

HQ city

Linyi

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Active Pharmaceutical Ingredients (API) Sales: Luoxin manufactures and sells bulk APIs including cephalosporins, quinolones, antivirals, respiratory, digestive, nervous system, endocrine, cardiovascular, antipyretic/analgesic, and oncology APIs to pharmaceutical manufacturers domestically and internationally. International registration and DMF available for multiple products, with exports to India, Japan, Korea, Vietnam, Egypt, and other markets.
2. Finished Dosage Form Products: The company markets over 300 finished dosage form products including tablets, capsules, injectable solutions, freeze-dried powder injections, sprays, aerosols, prefilled syringes across 48 national new drugs. Products are distributed through the company's domestic sales network covering all provinces in China.
3. Licensed Product Commercialization: Luoxin acquires exclusive rights to develop, manufacture, and commercialize innovative products (e.g., Budesolv®, Winuf®, Tegoprazan) in China from international partners, paying upfront payments, milestone payments, and tiered royalties based on net sales.
4. Healthcare Services: Luoxin Group integrates pharmaceutical R&D, manufacture, sales, and healthcare services as a healthcare conglomerate.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Shandong Luoxin Pharmaceutical Group manufactures and sells active pharmaceutical ingredients (APIs) and finished dosage forms across more than 10 therapeutic categories including anti-infectives, respiratory, digestive, nervous system, endocrine, cardiovascular, and oncology. The company operates three manufacturing bases with over 50 production lines producing tablets, capsules, injectables, freeze-dried powder injections, sprays, aerosols, and prefilled syringes, marketing over 300 products including 48 national new drugs. Its flagship innovation drug Tegoprazan (Taixinzan®) is China's first P-CAB approved for three indications.

Product overview

Luoxin Pharmaceutical Group is a large-scale pharmaceutical conglomerate integrating drug R&D, manufacturing, trading, and healthcare services. The company operates a comprehensive product portfolio comprising: (1) innovative drugs including Tegoprazan tablets (Taixinzan®, a P-CAB with three approved indications for H. pylori, reflux esophagitis, and duodenal ulcer), Rebeprazole Sodium Enteric-coated Tablets, and LX22001 injection (in clinical development); (2) licensed products including Winuf® three-chamber TPN and Budesolv® Budesonide Nasal Spray; (3) over 40 active pharmaceutical ingredient (API) product lines covering anti-infectives (cephalosporins, quinolones, carbapenems), antivirals, respiratory, digestive, neurological, endocrine, cardiovascular, oncology, and antipyretic-analgesic categories. The company holds 309 drug production licenses, 48 new drug certificates, and markets over 300 products.

Differentiator

Problem solved

Functional benefit

Products and services

• Tegoprazan Tablets (替戈拉生片, brand name Taixinzan® / 泰欣赞®) National Category 1 innovative drug; Potassium-Competitive Acid Blocker (P-CAB) for treatment of reflux esophagitis, duodenal ulcer, and Helicobacter pylori infection. Indicated for patients with acid-related gastrointestinal diseases.
• Rebeprazole Sodium Enteric-coated Tablets (雷贝拉唑钠肠溶片, 20mg) New-generation non-enzymatic pathway-metabolized proton pump inhibitor (PPI) for acid suppression treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, and related conditions.
• LX22001 Injection (注射用LX22001) Tegoprazan injectable formulation for acid suppression treatment; clinical applications include surgical and inpatient settings; positioned as potentially the world's first P-CAB injection formulation.
• Winuf® (Three-chamber Total Parenteral Nutrition Product) Three-chamber total parenteral nutrition (TPN) product containing refined fish oil for patients unable to receive enteral nutrition; applicable to patients with malnutrition under high-dose radiotherapy/chemotherapy and those with severe digestive dysfunction.
• Budesolv® (Budesonide Nasal Spray / 布地奈德鼻喷雾剂) Corticosteroid budesonide nasal spray based on Marinosolv® technology platform for treatment of allergic rhinitis.
• Cephalosporin API Series (头孢类原料药系列) Active pharmaceutical ingredients series comprising over 30 cephalosporin APIs including Cefoperazone Sodium, Cefuroxime Sodium, Ceftizoxime Sodium, Cefepime Hydrochloride, Ceftazidime, Cefamandole Nafate, Ceftriaxone Sodium, Cefotaxime Sodium, Cefoxitin Sodium, and others, with multiple international DMF registrations and CGMP certifications.
• Quinolone API Series (喹诺酮类原料药系列) Anti-infective active pharmaceutical ingredients series including Moxifloxacin Hydrochloride, Teriflunomide, Baloxavir, and Prulifloxacin for formulation into finished anti-infective products.
• Respiratory System APIs (呼吸系统原料药) Active pharmaceutical ingredients for respiratory system diseases including Ambroxol Hydrochloride and Ciclesonide.
• Digestive System APIs (消化系统原料药) Active pharmaceutical ingredients for digestive system treatments including Omeprazole Enteric-coated Pellets, Lansoprazole, Pantoprazole Sodium, Esomeprazole Sodium, and Rabeprazole Sodium proton pump inhibitor APIs.
• Nervous System APIs (神经系统原料药) Active pharmaceutical ingredients for nervous system drugs including Idarubicin, Midazolam Hydrochloride, Donepezil Hydrochloride, and Olanzapine.
• Oncology APIs (抗肿瘤原料药) Anti-tumor active pharmaceutical ingredients including Gemcitabine Hydrochloride, Irinotecan Hydrochloride, Oxaliplatin, Erlotinib Hydrochloride, Sorafenib Tosylate, Gefitinib, Dasatinib, Lapatinib Ditosylate, Capecitabine, Bortezomib, and Lenalidomide for cancer therapy formulations.
• Cardiovascular System APIs (心血管系统原料药) Active pharmaceutical ingredients for cardiovascular drugs including Simvastatin, Clopidogrel, Fasudil Hydrochloride, and Tirofiban.
• Endocrine System APIs (内分泌系统原料药) Active pharmaceutical ingredients for endocrine system drugs including Voglibose, Nateglinide, and Levothyroxine Sodium.
• Antipyretic-Analgesic APIs (解热镇痛抗炎原料药) Active pharmaceutical ingredients for antipyretic, analgesic, and anti-inflammatory drugs including Paracetamol, Losartan Potassium, and Parecoxib.
• Antiviral APIs (抗病毒原料药) Antiviral active pharmaceutical ingredients including Ganciclovir, Lamivudine, Entecavir, and Telbivudine for antiviral drug formulations.

Quantifiable outcome

• P-CAB tegoprazan demonstrated 93.5% Hp eradication rate vs 86.4% for esomeprazole in Phase III clinical trials
• +3 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

16 partnerships are on record, tiered core and minor.

• Marinomed Biotech AG (Austria)coreTechnology or Integration · 19 October 2021On October 19, 2021, Luoxin signed a licensing agreement with Austria-based Marinomed Biotech AG, whereby Shandong Luoxin gained exclusive rights for the development, manufacture, and commercialization of Budesolv® (Budesonide Nasal Spray) in China (including mainland, Hong Kong, Macao SAR, and Taiwan region). Shandong Luoxin shall pay an upfront payment of USD 2,000,000, plus development and sales milestone payments up to USD 20 million, and tiered royalties based on net sales. Budesolv® is the first product from Marinomed's proprietary Marinosolv® platform.
• HK inno.N Corporation (formerly CJ HealthCare Corporation, Korea)coreTechnology or Integration · 24 June 2021On June 24, 2021, Luoxin signed a cooperation agreement with HK inno.N Corporation (formerly CJ HealthCare Corporation) for exclusive rights to develop, manufacture, and commercialize Tegoprazan injections in China. Shandong Luoxin will pay up to US$5 million in total down payments and sales milestone payments. Tegoprazan injections are not yet available anywhere worldwide. The collaboration began in 2015 with agreement on Tegoprazan oral form; the injectable form represents a pipeline expansion.
• JW Holdings (Korea)coreTechnology or Integration · 26 October 2020In October 2020, Luoxin signed an exclusive license and distribution agreement with JW Holdings (Korean exchange: 096760), gaining exclusive rights to develop and commercialize Winuf® (three-chamber total parenteral nutrition product) in Chinese mainland, Hong Kong, and Macau. Winuf® contains refined fish oil and is the first Asian TPN product certified by European GMP. JW Holdings received upfront payment and sales milestone payments plus tiered royalties from Luoxin. The domestic sales of Winuf® in South Korea were KRW 55.7 billion last year.
• Aurobindo Pharma (India)coreStrategic or Co-development Partner · 23 December 2018On December 23, 2018, Luoxin reached an agreement with Aurobindo Pharma Co., Ltd. (India, publicly listed since 1992, top 5 generic pharmaceutical company globally) to establish a joint venture company in China for R&D and manufacturing of respiratory products. Aurobindo will transfer respiratory products and technical know-hows with technologic barriers to China for local manufacturing. The JV company will possess products approved by US FDA and EMA and manufacture respiratory products to supply China, US, and EU markets.
• CJ HealthCare Corporation (Korea)coreTechnology or Integration · 1 October 2015In October 2015, Luoxin entered into an agreement with CJ HealthCare Corporation (now HK inno.N Corporation) granting Luoxin exclusive rights to develop, manufacture, and commercialize LXI-15028 (tegoprazan) in China. The Phase III clinical trial met primary endpoint in December 2019, evaluating efficacy and safety for erosive esophagitis patients vs Esomeprazole.
• Shenyang Pharmaceutical UniversitycoreStrategic or Co-development PartnerLuoxin has built long-term stable cooperative relations with Shenyang Pharmaceutical University, establishing postdoctoral mobile workstation, teaching and training bases, practice bases, and employment bases. The university organized the inauguration of Luoxin pharmaceutical graduate employment base in October 2009 and held joint alumni association meetings at the company in November 2016.
• Zhejiang Hisun Pharmaceutical Co., Ltd.minorStrategic or Co-development PartnerListed as a cooperative partner. Hisun Pharmaceutical is one of China's leading pharmaceutical companies, cooperating with Luoxin in various pharmaceutical business activities.
• Shandong Lukang Pharmaceutical Co., Ltd.minorStrategic or Co-development PartnerListed as a cooperative partner of Luoxin Pharmaceutical.
• Qilu Antibiotics Pharmaceutical Co., Ltd.minorStrategic or Co-development PartnerListed as a cooperative partner of Luoxin Pharmaceutical.
• Joincare Pharmaceutical Industry GroupminorStrategic or Co-development PartnerListed as a cooperative partner of Luoxin Pharmaceutical.
• Guangxi Kelun Pharmaceutical Co., Ltd.minorStrategic or Co-development PartnerListed as a cooperative partner of Luoxin Pharmaceutical.
• Chinese Academy of SciencesminorStrategic or Co-development PartnerListed as a cooperative partner of Luoxin Pharmaceutical. The company has also jointly developed anti-cancer drugs with Shanghai Institute of Materia Medica of Chinese Academy of Sciences and Fudan University since November 2015.
• WuXi AppTecminorStrategic or Co-development PartnerListed as a cooperative partner of Luoxin Pharmaceutical.
• China National Pharmaceutical Group Corporation (Sinopharm)minorStrategic or Co-development PartnerListed as a cooperative partner of Luoxin Pharmaceutical.
• China Pharmaceutical UniversityminorStrategic or Co-development PartnerListed as a cooperative partner of Luoxin Pharmaceutical.
• Harbin Pharmaceutical GroupminorStrategic or Co-development PartnerListed as a cooperative partner of Luoxin Pharmaceutical.

Scale indicators13 records

Recent moves13 records

Expansion highlights6 records

Direct peers

• Livzon Pharmaceutical Group Inc. Chinese pharma group with a vertically integrated API plus finished-dose business in anti-infectives, oncology, digestive, and reproductive health, plus a biosimilars/innovation arm. Same horizontal segmentation, similar API-first positioning.
• Shandong Xinhua Pharmaceutical Co., Ltd. Shandong-headquartered pharmaceutical manufacturer overlapping with Luoxin in chemical-API (notably antipyretic-analgesic and cephalosporin/intermediate) APIs and finished-dose generics. Strongly comparable on geography, manufacturing footprint, and product overlap.
• Luye Pharma Group Ltd. Mid-cap Chinese pharma with a branded specialty portfolio (oncology, cardiovascular, CNS) plus licensed international assets and nationwide distribution. Direct structural peer to Luoxin given mixed branded/generic model and reliance on in-licensing to fill the pipeline.
• China Grand Pharmaceutical and Healthcare Holdings Ltd. Diversified Chinese pharmaceutical group combining branded cardio/respiratory products with API manufacturing and nationwide hospital sales coverage. Highly comparable to Luoxin on therapeutic breadth, API+finished-dose mix, and dependence on China hospital channels.
• Zhejiang Hisun Pharmaceutical Co., Ltd. Listed Luoxin partner and similarly sized domestic pharma combining generic APIs (notably antitumor and anti-infective) with finished-dose formulations. Comparable on API breadth, anti-infective/anticancer focus, and Chinese A-share listed status.

Broad incumbents

• Jiangsu Hengrui Pharmaceuticals Co., Ltd. China's largest domestic innovative pharma with a deep oncology and specialty-care pipeline plus injectable manufacturing. Operating model (China-focused R&D, hospital commercialization, generics + innovation mix) broadly mirrors Luoxin at materially larger scale.
• Sino Biopharmaceutical Ltd. Large diversified Chinese pharma with hepatology/oncology/cardio branded products and biologics/biosimilars. Overlaps with Luoxin on horizontal therapeutic breadth and hospital channel but is significantly larger and more biologics-tilted.
• CSPC Pharmaceutical Group Ltd. Hong Kong-listed Chinese pharma with a much larger oncology/neurology branded franchise plus injectable manufacturing. Broader scope than Luoxin but operates in the same hospital-channel, integrated-manufacturing space.
• Shanghai Pharmaceuticals Holding Co., Ltd. Major Chinese state-affiliated pharmaceutical and distribution conglomerate. Luoxin's Runxin Pharmaceutical distribution arm and Shandong-based finished-dose manufacturing mirror its integrated manufacturing-and-distribution model, though Shanghai Pharma operates at city/province distribution scale.

Emerging players

• Phathom Pharmaceuticals, Inc. US-focused specialty pharma commercializing Tegoprazan (Voquezna) under license from HK inno.N — the same molecule Luoxin holds China rights to. Competes with Luoxin on P-CAB mechanism at the global/regional level and validates the P-CAB demand thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries8 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shandong Luoxin Pharmaceutical Group